From: "sonny darling" <diedrabrowing@wvbr.com>
To: "Ervin Lorett" <vasvir@iit.demokritos.gr>
Subject: EqyEu This st0ck has everything going for it
Date: Sun, 27 Feb 2005 08:56:35 +0300
MIME-Version: 1.0
Content-Type: text/html;
	charset="iso-8859-7"
Content-Transfer-Encoding: quoted-printable
X-Priority: 3
X-MSMail-Priority: Normal
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2900.2527

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<META HTTP-EQUIV=3D"Content-Type" CONTENT=3D"text/html; =
charset=3Dus-ascii">
<META NAME=3D"Generator" CONTENT=3D"MS Exchange Server version =
6.5.7036.0">
<TITLE>EqyEu This st0ck has everything going for it</TITLE>
</HEAD>
<BODY>
<!-- Converted from text/plain format -->

<P><FONT SIZE=3D2>Martin Nutraceuticals Commences Expansion in Global =
Nutraceutical<BR>
Marketplace.<BR>
<BR>
Watch MTNU on Thursday!<BR>
<BR>
Martin Nutraceuticals Inc. (MTNU)<BR>
Approximate Float: 2.5 Million<BR>
Currently trading at: 0.91<BR>
30 Day Projection: 2.00<BR>
<BR>
Martin Nutraceuticals Commences Expansion in Global Nutraceutical<BR>
Marketplace.<BR>
<BR>
Press Release Source: Martin Nutraceuticals Inc.<BR>
<BR>
Wednesday February 23, 12:01 pm ET<BR>
<BR>
RENO, Nev., Feb. 23, 2005 PRIMEZONE. Martin Nutraceuticals Inc. =
(MTNU)<BR>
is a company focused on developing natural and alternative medicine<BR>
products that provide better health for individuals through the use =
of<BR>
their wide range of products, which aid in joint therapy, digestive<BR>
therapy, WeightControl, blood circulation and alertness, and overall<BR>
improved<BR>
functioning of the b0dy.<BR>
<BR>
The flagship product which is based on Joint Therapy is used to aid =
in<BR>
joint and general arthritic pain. Over 65 million Americans suffer =
from<BR>
arthritis and osteoporosis. For several years, Dr. A. W. Martin DC,<BR>
PhD, RNCP, DNM, a world renowned researcher has studied the effects =
of<BR>
enzyme therapy on pain and inflammation. Dr. Martin has developed a =
unique<BR>
blend of proprietary and patented ``systemic oral enzymes'' designed =
to<BR>
provide superior anti-inflammatory benefits. Studies have shown that<BR>
Dr. Martin's Joint Therapy, proprietary enzyme formula reduces pain =
and<BR>
inflammation in 80% of patients who are diagnosed with Osteoarthritis =
of<BR>
the knees in less than 6-weeks.<BR>
<BR>
In another study conducted the patient Fibromyalgia -- a severe =
muscle<BR>
pain syndrome that affects more than 20 million North Americans -- =
90%<BR>
of patients reported relief from swelling and pain within 4-weeks of<BR>
using Dr. Martin's Joint Therapy formula.<BR>
<BR>
The nutraceuticals market has grown steadily at an incredible rate =
of<BR>
15-20% annually since 1998. Currently in North America, over 3.9 =
billion<BR>
is spent on over-the-counter and prescription medication for =
arthritis,<BR>
joint and muscle related pain alone. Since Dr. Martin's foray into =
the<BR>
nutraceuticals market, Dr. Martin's products have amassed sales over =
35<BR>
million. It is with this track record and knowledge that Martin<BR>
Nutraceuticals has re-branded many of Dr. Martin's successful formulas =
and<BR>
is<BR>
poised to unveil them onto an international platform.<BR>
<BR>
In the weeks and months to come, the company will be unveiling new<BR>
product lines, various sales targets, contracts, distribution =
agreements<BR>
and clinical data.<BR>
<BR>
<BR>
About MTNU:<BR>
<BR>
MTNU is becoming quickly recognized in the nutraceutical marketplace<BR>
which will surpass 74.4 billion in the year 2007.&nbsp; With a growing =
demand<BR>
for nutraceutical products that provide not only health benefits, =
but<BR>
also prevent and provide treatment for disease, MTNU provides high<BR>
quality products that use proprietary and patented oral systemic =
enzymes<BR>
that help in the rapid absorption of the product, resulting in =
incredibly<BR>
swift, and effective results to symptoms including:<BR>
<BR>
JointPain<BR>
Cardiovascular Irregularities<BR>
Digestive Irregularities<BR>
Anti-Oxidization<BR>
WeightL0ss<BR>
<BR>
MTNU offers individuals a wide array of reliable and effective<BR>
nutraceuticals. Martin Nutraceuticals has created a family of =
complimentary<BR>
<BR>
medicine and supplementation that has helped thousands of people =
suffering<BR>
from arthritis and general jointpain, poor circulation, tiredness,<BR>
obesity and digestive complications.&nbsp; By integrating proprietary =
oral<BR>
systemic enzymes, MTNU has revolutionized the consumption of =
naturopathic<BR>
supplementation. With the use of these enzymes with products such as<BR>
Joint Therapy, MTNU has designed an innovative way to treat arthritis =
and<BR>
general jointpain.<BR>
<BR>
Millions of people in North America suffer from some degree of =
general<BR>
jointpain.&nbsp; According to the Arthritis Society, arthritis is =
North<BR>
America's most common ailment, with over 44 million North Americans<BR>
suffering.&nbsp; The Wall Street Journal, in the April 19th, 1999 issue =
states<BR>
that<BR>
Aspirin, Ibuprofen (Cox 1) Vioxx, Celebrex (Cox 2) killed 20,000<BR>
Americans a year and put another 100,000 in the hospital suffering =
with<BR>
drug<BR>
side effects including: liver damage, kidney damage and intestinal<BR>
hemorrhaging.&nbsp; With many of these products being pulled and =
highly<BR>
regulated because of the potential of deadly side effects, sufferers =
of<BR>
jointpain are seeking a natural, healthy alternative to aid in their<BR>
suffering.<BR>
<BR>
MTNU has developed a proprietary therapeutic product, Joint Therapy,<BR>
which is able to benefit all types of arthritis from: Rheumatoid<BR>
Arthritis, sports injuries, pelvic inflammation to cardiac =
inflammation.<BR>
MTNU's<BR>
unique marketing program consists of heavily aired infomercials, =
direct<BR>
mailorder marketing and large pharmaceutical and retail chains.<BR>
<BR>
Will MTNU explode higher as more and more investors become aware of =
the<BR>
stock?&nbsp; If you think so, you may not want to wait until it is too =
late.<BR>
Remember, timing your trade is critical.<BR>
<BR>
Good Luck and Happy Trading.<BR>
<BR>
<BR>
Information within this publication contains future looking =
statements<BR>
within the meaning of Section 27A of the Securities Act of 1933 and<BR>
Section 21B of the Securities Exchange Act of 1934.&nbsp; Any statements =
that<BR>
express or involve discussions with respect to predictions,<BR>
expectations, beliefs, plans, projections, objectives, goals, =
assumptions<BR>
or future<BR>
events or performance are not statements of historical fact and may =
be<BR>
future looking statements. Future looking statements are based on<BR>
expectations, estimates and projections at the time the statements are =
made<BR>
<BR>
that involve a number of risks and uncertainties which could cause<BR>
actual results or events to differ materially from those presently<BR>
anticipated. Future looking statements in this action may be =
identified<BR>
through<BR>
the use of words such as projects, foresee, expects, will, =
anticipates,<BR>
estimates, believes, understands or that by statements indicating<BR>
certain actions may, could, or might occur. These future-looking =
statements<BR>
<BR>
are based on information currently available and are subject to a<BR>
number of risks, uncertainties and other factors that could cause MTNU =
's<BR>
actual results, performance, prospects or opportunities to differ<BR>
materially from those expressed in, or implied by, these =
future-looking<BR>
statements. As with many microcap stocks, today's company has =
additional<BR>
risk<BR>
factors that raise doubt about its ability to continue as a going<BR>
concern. MTNU is not a reporting company registered under the =
Securities<BR>
Act<BR>
of 1934 and hence there is limited public information available =
about<BR>
the company. These risks, uncertainties and other factors include,<BR>
without limitation, the Company's growth expectations and ongoing =
funding<BR>
requirements, and specifically, the Company's growth prospects with<BR>
scalable customers. Other risks include the Company's limited =
operating<BR>
history, the Company's history of operating losses, consumers' =
acceptance,<BR>
the Company's use of licensed technologies, risk of increased<BR>
competition, the potential need for additional financing, the =
conditions<BR>
and<BR>
terms of any financing that is consummated, the limited trading market =
for<BR>
the Company's securities, the possible volatility of the Company's<BR>
stock price, the concentration of ownership, and the potential =
fluctuation<BR>
in the Company's operating results. The publisher of this report =
does<BR>
not represent that the information contained in this message states =
all<BR>
material facts or does not omit a material fact necessary to make =
the<BR>
statements therein not misleading. All information provided within =
this<BR>
report pertaining to investing, stocks, securities must be =
understood<BR>
as information provided and not investment advice. The publisher of =
this<BR>
newsletter advises all readers and subscribers to seek advice from a<BR>
registered professional securities representative before deciding to<BR>
trade in stocks featured within this report. None of the material =
within<BR>
this report shall be construed as any kind of investment advice or<BR>
solicitation. Many of these companies are on the verge of bankruptcy. =
You<BR>
can<BR>
lose all your money by investing in this stock. The publisher of =
this<BR>
report is not a registered investment expert. Subscribers should not<BR>
view information herein as legal, tax, accounting or investment =
advice.<BR>
Any reference to past performance(s) of companies are specially =
selected<BR>
to be referenced based on the favorable performance of these =
companies.<BR>
You would need perfect timing to achieve the results in the examples<BR>
given. There can be no assurance of that happening. Remember, as =
always,<BR>
past performance is not indicative of future results and a thorough =
due<BR>
diligence effort, including a review of a company's filings at sec =
gov<BR>
or edgar-online com when available, should be completed prior to<BR>
investing. All factual information in this report was gathered from =
public<BR>
sources, including but not limited to Company Websites and Company =
Press<BR>
Releases. The publisher of this report believes this information to =
be<BR>
reliable but can make no assurance as to its accuracy or =
completeness.<BR>
Use of the material within this report constitutes your acceptance =
of<BR>
these terms.&nbsp; In compliance with the Securities Act of 1933, =
Section17<BR>
b, The publisher of this newsletter discloses the receipt of ten<BR>
thousand dollars from a third party, not an officer, director or =
affiliate<BR>
shareholder for the circulation of this report.&nbsp; Be aware of an =
inherent<BR>
conflict of interest resulting from such compensation due to the =
fact<BR>
that this is a paid advertisement and is not without bias.The party =
that<BR>
paid us has a position in the stock they will sell at anytime =
without<BR>
notice. This could have a negative impact on the price of the stock.<BR>
<BR>
<BR>
<BR>
<BR>
to Alex's grave, &quot;poor impulse control&quot;? Maybe it was that, =
too, he says<BR>
when he returns, hands<BR>
He says he understandsthe meaning of grief now; less clear to him is =
the<BR>
meaning of recovery.<BR>
<BR>
feel better?&quot; he says. &quot;I have no idea.&quot;It is a question =
not only for<BR>
Arredondo, but for<BR>
gohwx.cn1srguqwrfgwqgx.uhwcrirve33vcbife.ubyrhckq<BR>
<BR>
<BR>
</FONT>
</P>

</BODY>
</HTML>
